Evolus, Inc. (EOLS) vs Evotec AG (EVO)

Evolus, Inc. and Evotec AG are both Drug Manufacturers Specialty & Generic companies. Evolus, Inc. and Evotec AG are of similar size ($539.9M and $519.2M). Evolus, Inc. grew revenue faster over the last twelve months: 13.9% against 2.15%. Evolus, Inc. has the higher net margin (−10.9% vs −26.2%) and the lower return on invested capital (−14.5% vs 0.00%). Across the 17 metrics below, Evolus, Inc. leads on 10 and Evotec AG on 7.

Valuation

Metric EOLS EVO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.66 0.64 2.25
P/B n/m 0.72 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 2.02 0.65 2.56
Earnings yield (6.52%) (40.90%) (2.99%)
Free cash flow yield (4.17%) (36.14%) 0.00%

Profitability

Metric EOLS EVO Drug Manufacturers Specialty & Generic median
Gross margin 66.74% 11.42% 53.94%
Operating margin (5.90%) (21.35%) 0.00%
Net margin (10.85%) (26.20%) 0.00%
Free cash flow margin (6.92%) 0.00% 0.00%
Return on equity 138.57% 0.00% (0.40%)
Return on assets (14.40%) 0.00% (3.32%)
Return on invested capital (14.47%) 0.00% 0.00%

Growth

Metric EOLS EVO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 13.87% 2.15% 10.01%
EPS growth (last fiscal year) 1.23% 44.89% —
Revenue growth, 5-year CAGR 39.36% 9.28% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EOLS EVO Drug Manufacturers Specialty & Generic median
Debt to equity (5.07) 0.72 0.05
Current ratio 1.70 2.33 2.31
Net debt to EBITDA (4.08) (0.64) 0.85

Dividend

Metric EOLS EVO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric EOLS EVO Drug Manufacturers Specialty & Generic median
Market cap 519.16m 539.87m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack